



May 16, 2022

Re : Updated information regarding Nasonex[®] (mometasone furoate monohydrate aqueous nasal spray) - DINs: 02238465

Dear Healthcare Professional,

This letter is to inform you of a change in indication to Organon's drug product, Nasonex[®] (mometasone furoate monohydrate aqueous nasal spray).

Nasonex[®] is indicated for:

- use in children between the ages of 3 and 11 years to treat the symptoms of seasonal or perennial allergic rhinitis.
- use in adults and children 12 years of age and older as adjunctive treatment to antibiotics in acute episodes of rhinosinusitis, where signs or symptoms of bacterial infection are present.
- use in adults and children 12 years of age and older in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis where signs or symptoms of bacterial infection are not present.
- the treatment of nasal polyps in adult patients 18 years of age or older

Nasonex[®] was previously also indicated for adults and children 12 years of age and older for the treatment of symptoms of seasonal or perennial allergic rhinitis. The change to the Nasonex[®] indication was a result of a change to the prescription drug status of mometasone furoate. This ingredient was approved as a non-prescription medication for patients 12 years and older for the treatment of symptoms of seasonal or perennial allergic rhinitis. Following a partial prescription to non-prescription (OTC) switch, the indication that is being switched is no longer a prescription drug indication. The Nasonex[®] product monograph was therefore revised accordingly.

For the complete prescribing information and information available for the patients/caregivers please consult the [Nasonex[®] Product Monograph](#). The Product Monograph can be found on the [Organon Website](#), or by contacting Organon Canada at 1-844-820-5468.

Should you have medical enquiries regarding Nasonex[®], please contact our Medical Information Department at 1-844-820-5468.